|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||15.15 - 15.27|
|52 Week Range||11.65 - 21.05|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.59 (3.80%)|
|Ex-Dividend Date||Apr 28, 2021|
|1y Target Est||17.20|
Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.
Today, our planet faces the challenge of using fewer natural resources while feeding a growing population — predicted to reach almost 10 billion by 2050. The day-to-day realities of farming, agricu...
Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer’s subsidiary BlueRock Therapeutics’s trial will eventually enroll 10 participants. Patients will have dopamine-producing cells surgically implanted into a part of the brain called the putamen. The trial will primarily examine the safety and tolerability of DA01 cell transplantation a year after the pro